About that target-date funds proposal ...
Ten years later.
Running through the numbers.
Why buy Nuveen?
What Michael Lewis didn't write.
Fifteen years in four colored lines.
Michael Lewis takes on the stock market.
The great insights of the 1960s, half a century later.
The case for management teams.
The story is messier than the investment results will be.
The fourth in a four-part series.
The third in a four-part series.
How serious are they?
The second in a four-part series.
The first in a four-part series.
The painful math of taxable accounts.
Three reasons why.
What it does and does not do.
No, it's not the myRA.
On performance, not assets.
Thinking the once-unthinkable.
How Morningstar's Fund Managers of the Year perform after the fact.
The signals are mixed.
Has its time come?
Daring to be different.
Investing during retirement can benefit from complexity.
Assembling the pieces.
Two arguments against U.S. stocks.
Things look better after easing unrealistic assumptions.
The domino effect.
Montier snaps at smart beta and risk parity.
So far, it's working out.
ETFs take aim.
What the numbers suggest.
The argument for owning more stocks with age.
*Per Janus' marketing department.
Preparing for rising interest rates.
Has the company become too big?
The price isn't yet right.
Slow start, fast finish.
Yes--but that doesn't tell us much.
Which ETF is oddest?
The answer seems to be both.
When the answer is already known.
The Wall Street Journal poses the question.
The readers strike back.
The trials of the nonconforming--and nonperforming--money manager.
The time may be right (that is, wrong).
Learning from failure.
Bad timing, a limited investment strategy, and high costs.